Modern Investor Says XRP Is Going to $25, XRP Army Reacts
Crypto commentator The Modern Investor has put a number on XRP’s potential, and the figure is getting attention on X.
The prediction: XRP reaches $25. The community has responded with a range of views, from outright skepticism to suggestions the target is still too conservative.
Ripple’s Banking License
Ripple has made notable regulatory strides in the United States, and some community members see its banking license as a catalyst that could push valuations beyond what current price targets reflect.
The prediction from The Modern Investor has put a specific number in front of a community that holds strong and divided opinions on XRP’s trajectory. Whether $25 represents a ceiling or a floor remains the central debate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
